Beschreibung
The aim of this book is to review the available scientific evidence with aim of finding keys to overcome the therapeutic challenge associated with the emerging coronavirus global pandemic in 2020. As lopinavir/ritonavir is not available in many geographic areas, this evidence-based book recommends the use of teicoplanin with or without lopinavir/ritonavir. Teicoplanin can be used in the doses suggested by Sato et al (2006). A loading dose of 400 or 800 mg can be given on the first day, followed by maintenance dose of 400mg. We suggest that in areas where serial tests are available for asymptomatic patients, a dose of 400mg can be given for to days with aim of achieving early negative test and clearance of the virus, and thus reducing its spread.
Autorenporträt
Aamir Jalal Al Mosawi, advisor doctor at Baghdad Medical City, and the Head of Iraq Headquarter of Copernicus Scientists International Panel. He is the founding editor of an international peer-reviewed medical journal "The New Iraqi Journal of Medicine (2005-2013) [Scopus] ".
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
